Literature DB >> 24426694

Systemic therapy in head and neck cancer: changing paradigm.

Samit Purohit1, Rohan Bhise2, D Lokanatha2, K Govindbabu2.   

Abstract

Head and neck cancers comprise a heterogenous group of cancers that require a multidisciplinary approach. Last few decades have seen an increasing role of chemotherapy with intent of treatment shifting from palliation to cure. We performed a thorough search online and offline for all relevant articles of chemotherapy in head and neck cancer. Cancers of nasopharynx and salivary glands were excluded.

Entities:  

Keywords:  Chemoevolution in head and neck cancer; Chemtherapy in head and neck cancer; HPV; MACH-NC; PET-CT

Year:  2012        PMID： 24426694      PMCID： PMC3578550          DOI： 10.1007/s13193-012-0197-4

Source DB:  PubMed          Journal:  Indian J Surg Oncol        ISSN： 0975-7651


  40 in total

1.  Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck.

Authors:  Roy S Herbst; Matthew Arquette; Dong M Shin; Karel Dicke; Everett E Vokes; Nozar Azarnia; Waun Ki Hong; Merrill S Kies
Journal:  J Clin Oncol       Date:  2005-07-11       Impact factor: 44.544

2.  Docetaxel: an active drug for squamous cell carcinoma of the head and neck.

Authors:  A I Dreyfuss; J R Clark; C M Norris; R M Rossi; J W Lucarini; P M Busse; M D Poulin; L Thornhill; R Costello; M R Posner
Journal:  J Clin Oncol       Date:  1996-05       Impact factor: 44.544

3.  Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.

Authors:  Jochen H Lorch; Olga Goloubeva; Robert I Haddad; Kevin Cullen; Nicholas Sarlis; Roy Tishler; Ming Tan; John Fasciano; Daniel E Sammartino; Marshall R Posner
Journal:  Lancet Oncol       Date:  2011-01-11       Impact factor: 41.316

4.  Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study.

Authors:  A A Forastiere; B Metch; D E Schuller; J F Ensley; L F Hutchins; P Triozzi; J A Kish; S McClure; E VonFeldt; S K Williamson
Journal:  J Clin Oncol       Date:  1992-08       Impact factor: 44.544

5.  Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck.

Authors:  W K Hong; S M Lippman; L M Itri; D D Karp; J S Lee; R M Byers; S P Schantz; A M Kramer; R Lotan; L J Peters
Journal:  N Engl J Med       Date:  1990-09-20       Impact factor: 91.245

6.  Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group.

Authors:  P Schöffski; G Catimel; A S Planting; J P Droz; J Verweij; D Schrijvers; L Gras; A Schrijvers; J Wanders; A R Hanauske
Journal:  Ann Oncol       Date:  1999-01       Impact factor: 32.976

7.  Cisplatinum and bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: a randomised factorial phase III controlled trial.

Authors:  R P Morton; F Rugman; E B Dorman; P J Stoney; J A Wilson; M McCormick; A Veevers; P M Stell
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

8.  A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck.

Authors:  C Jacobs; G Lyman; E Velez-García; K S Sridhar; W Knight; H Hochster; L T Goodnough; J E Mortimer; L H Einhorn; L Schacter
Journal:  J Clin Oncol       Date:  1992-02       Impact factor: 44.544

Review 9.  Overview of combined modality therapies for head and neck cancer.

Authors:  I W Dimery; W K Hong
Journal:  J Natl Cancer Inst       Date:  1993-01-20       Impact factor: 13.506

10.  Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d'Etude des Tumeurs de la Tête et du Cou (GETTEC).

Authors:  C Domenge; C Hill; J L Lefebvre; D De Raucourt; B Rhein; P Wibault; P Marandas; B Coche-Dequeant; M Stromboni-Luboinski; H Sancho-Garnier; B Luboinski
Journal:  Br J Cancer       Date:  2000-12       Impact factor: 7.640
View more
  3 in total

Review 1.  Emerging drugs for head and neck cancer.

Authors:  Yihui Wen; Jennifer R Grandis
Journal:  Expert Opin Emerg Drugs       Date:  2015-03-31       Impact factor: 4.191

2.  The influence of dental treatment on the development of osteoradionecrosis after radiotherapy by modern irradiation techniques.

Authors:  Ramona Schweyen; Andreas Stang; Andreas Wienke; Alexander Eckert; Thomas Kuhnt; Jeremias Hey
Journal:  Clin Oral Investig       Date:  2017-01-13       Impact factor: 3.573

Review 3.  Recent Progress in Therapeutic Treatments and Screening Strategies for the Prevention and Treatment of HPV-Associated Head and Neck Cancer.

Authors:  Sonia N Whang; Maria Filippova; Penelope Duerksen-Hughes
Journal:  Viruses       Date:  2015-09-17       Impact factor: 5.048
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.